WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Clontech
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
BioSpace | March 12, 2020
Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...
Publicist 360 | April 08, 2020
IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...
Industry Outlook
Businesswire | July 21, 2023
Sangamo Therapeutics, Inc. a clinical-stage genomic medicine company and Chroma Medicine, Inc. a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deployin...
MedTech
businesswire | August 31, 2023
Watchmaker Genomics, a supplier of innovative products for molecular analysis, today announced a multi-year, co-exclusive agreement with Exact Sciences Corporation, a leading provider of cancer screening and diagnostic tests, to develop and commercialize the breakthrough DNA methylation analysis technology, TET-assisted pyridine borane sequencing (TAPS). Watchmaker will apply its expertise in engineering DNA-modifying enzymes to further improve the TAPS chemistry, ultimately enabling advan...
Video
Cell and Gene Therapy, Industrial Impact
Whitepaper
Medical
Cell and Gene Therapy
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE